Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.
Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis
Atherosclerosis, Biologics, Biopharmaceutical, Blood Vessels, Business, Cholesterol Lowering, Contract Development Manufacturing Organization (CDMO), Incubators, Innovation, Plaque, R&D, Statins, Vascular DIseaseCelltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
Kowa Pharmaceuticals America Inc. today announced publication of results of the INTREPID Trial (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) in The Lancet HIV. Results of the Phase 4 trial showed that LIVALO (pitavastatin) 4 mg was superior to pravastatin 40 mg in reducing LDL cholesterol (LDL-C) in adults with HIV and dyslipidemia and had a comparable safety profile.
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
Here are five company stocks that some industry analysts say are under the radar and/or could be a great bargain in 2016 per BioSpace.com sources …
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
A difficult feat to accomplish in business is to make dramatic change in the midst of current success. History is littered with companies that were once on top of the […]
Many of the drugs that are sold over-the-counter (OTC) began life as prescription medications. Anti-ulcer/heartburn drugs such as the histamine H2 antagonist, Zantac, and the proton-pump inhibitor, Prilosec, were first […]
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or […]
Does Steve Nissen, an outspoken critic of inappropriate industry influence in medicine, have his own conflict of interest problem? This week Nissen, the chief of cardiology at the Cleveland Clinic, was […]
